ALK and lung carcinoma: In NUGC4 cell models, we evaluated the effect of crizotinib (50 mg/kg), since we have previously reported that 25 mg/kg and 50 mg/kg of crizotinib inhibited the progression of peritoneal carcinomatosis produced by NUGC4 cells 23, and that of brain tumors produced by EML4‐ALK‐positive A925L lung cancer cells 15, respectively.